Excitingly, agonists of the Nrf2 signaling pathway, DMF, have entered the clinical study phase for the treatment of patients with pulmonary hypertension caused by systemic sclerosis (SSc) [96]. This evidence concerns the gene NFE2L2 and systemic sclerosis.